Literature DB >> 23825303

TCR-ligand koff rate correlates with the protective capacity of antigen-specific CD8+ T cells for adoptive transfer.

Magdalena Nauerth1, Bianca Weißbrich, Robert Knall, Tobias Franz, Georg Dössinger, Jeannette Bet, Paulina J Paszkiewicz, Lukas Pfeifer, Mario Bunse, Wolfgang Uckert, Rafaela Holtappels, Dorothea Gillert-Marien, Michael Neuenhahn, Angela Krackhardt, Matthias J Reddehase, Stanley R Riddell, Dirk H Busch.   

Abstract

Adoptive immunotherapy is a promising therapeutic approach for the treatment of chronic infections and cancer. T cells within a certain range of high avidity for their cognate ligand are believed to be most effective. T cell receptor (TCR) transfer experiments indicate that a major part of avidity is hardwired within the structure of the TCR. Unfortunately, rapid measurement of structural avidity of TCRs is difficult on living T cells. We developed a technology where dissociation (koff rate) of truly monomeric peptide-major histocompatibility complex (pMHC) molecules bound to surface-expressed TCRs can be monitored by real-time microscopy in a highly reliable manner. A first evaluation of this method on distinct human cytomegalovirus (CMV)-specific T cell populations revealed unexpected differences in the koff rates. CMV-specific T cells are currently being evaluated in clinical trials for efficacy in adoptive immunotherapy; therefore, determination of koff rates could guide selection of the most effective donor cells. Indeed, in two different murine infection models, we demonstrate that T cell populations with lower koff rates confer significantly better protection than populations with fast koff rates. These data indicate that koff rate measurements can improve the predictability of adoptive immunotherapy and provide diagnostic information on the in vivo quality of T cells.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23825303      PMCID: PMC3991308          DOI: 10.1126/scitranslmed.3005958

Source DB:  PubMed          Journal:  Sci Transl Med        ISSN: 1946-6234            Impact factor:   17.956


  30 in total

1.  Two antigenic peptides from genes m123 and m164 of murine cytomegalovirus quantitatively dominate CD8 T-cell memory in the H-2d haplotype.

Authors:  Rafaela Holtappels; Doris Thomas; Jürgen Podlech; Matthias J Reddehase
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

2.  Large numbers of dysfunctional CD8+ T lymphocytes bearing receptors for a single dominant CMV epitope in the very old.

Authors:  Qin Ouyang; Wolfgang M Wagner; Anders Wikby; Steffen Walter; Geraldine Aubert; Anthony I Dodi; Paul Travers; Graham Pawelec
Journal:  J Clin Immunol       Date:  2003-07       Impact factor: 8.317

3.  The human CD8 coreceptor effects cytotoxic T cell activation and antigen sensitivity primarily by mediating complete phosphorylation of the T cell receptor zeta chain.

Authors:  M A Purbhoo; J M Boulter; D A Price; A L Vuidepot; C S Hourigan; P R Dunbar; K Olson; S J Dawson; R E Phillips; B K Jakobsen; J I Bell; A K Sewell
Journal:  J Biol Chem       Date:  2001-07-03       Impact factor: 5.157

Review 4.  Parameters determining the efficacy of adoptive CD8 T-cell therapy of cytomegalovirus infection.

Authors:  Stefan Ebert; Jürgen Podlech; Dorothea Gillert-Marien; Kerstin M Gergely; Julia K Büttner; Annette Fink; Kirsten Freitag; Doris Thomas; Matthias J Reddehase; Rafaela Holtappels
Journal:  Med Microbiol Immunol       Date:  2012-09-13       Impact factor: 3.402

5.  Heterogeneous T-cell response to MAGE-A10(254-262): high avidity-specific cytolytic T lymphocytes show superior antitumor activity.

Authors:  V Dutoit; V Rubio-Godoy; P Y Dietrich; A L Quiqueres; V Schnuriger; D Rimoldi; D Liénard; D Speiser; P Guillaume; P Batard; J C Cerottini; P Romero; D Valmori
Journal:  Cancer Res       Date:  2001-08-01       Impact factor: 12.701

6.  Efficient gene transfer into primary human CD8+ T lymphocytes by MuLV-10A1 retrovirus pseudotype.

Authors:  W Uckert; C Becker; M Gladow; D Klein; T Kammertoens; L Pedersen; T Blankenstein
Journal:  Hum Gene Ther       Date:  2000-05-01       Impact factor: 5.695

7.  Reversible MHC multimer staining for functional isolation of T-cell populations and effective adoptive transfer.

Authors:  Michael Knabel; Tobias J Franz; Matthias Schiemann; Anna Wulf; Brigitte Villmow; Burkhard Schmidt; Helga Bernhard; Hermann Wagner; Dirk H Busch
Journal:  Nat Med       Date:  2002-06       Impact factor: 53.440

8.  Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes.

Authors:  Mark E Dudley; John R Wunderlich; Paul F Robbins; James C Yang; Patrick Hwu; Douglas J Schwartzentruber; Suzanne L Topalian; Richard Sherry; Nicholas P Restifo; Amy M Hubicki; Michael R Robinson; Mark Raffeld; Paul Duray; Claudia A Seipp; Linda Rogers-Freezer; Kathleen E Morton; Sharon A Mavroukakis; Donald E White; Steven A Rosenberg
Journal:  Science       Date:  2002-09-19       Impact factor: 47.728

9.  High efficiency TCR gene transfer into primary human lymphocytes affords avid recognition of melanoma tumor antigen glycoprotein 100 and does not alter the recognition of autologous melanoma antigens.

Authors:  Richard A Morgan; Mark E Dudley; Yik Y L Yu; Zhili Zheng; Paul F Robbins; Marc R Theoret; John R Wunderlich; Marybeth S Hughes; Nicholas P Restifo; Steven A Rosenberg
Journal:  J Immunol       Date:  2003-09-15       Impact factor: 5.422

10.  Retroviral vectors for high-level transgene expression in T lymphocytes.

Authors:  Boris Engels; Hakan Cam; Thomas Schüler; Stefano Indraccolo; Monika Gladow; Christopher Baum; Thomas Blankenstein; Wolfgang Uckert
Journal:  Hum Gene Ther       Date:  2003-08-10       Impact factor: 5.695

View more
  46 in total

1.  Spatial distribution and structural arrangement of a murine cytomegalovirus glycoprotein detected by SPDM localization microscopy.

Authors:  Patrick Müller; Niels A Lemmermann; Rainer Kaufmann; Manuel Gunkel; Daniel Paech; Georg Hildenbrand; Rafaela Holtappels; Christoph Cremer; Michael Hausmann
Journal:  Histochem Cell Biol       Date:  2014-02-07       Impact factor: 4.304

2.  Microfluidic platform for characterizing TCR-pMHC interactions.

Authors:  Max A Stockslager; Josephine Shaw Bagnall; Vivian C Hecht; Kevin Hu; Edgar Aranda-Michel; Kristofor Payer; Robert J Kimmerling; Scott R Manalis
Journal:  Biomicrofluidics       Date:  2017-11-14       Impact factor: 2.800

3.  Tumor-Infiltrating Merkel Cell Polyomavirus-Specific T Cells Are Diverse and Associated with Improved Patient Survival.

Authors:  Natalie J Miller; Candice D Church; Lichun Dong; David Crispin; Matthew P Fitzgibbon; Kristina Lachance; Lichen Jing; Michi Shinohara; Ioannis Gavvovidis; Gerald Willimsky; Martin McIntosh; Thomas Blankenstein; David M Koelle; Paul Nghiem
Journal:  Cancer Immunol Res       Date:  2017-01-16       Impact factor: 11.151

Review 4.  Refining human T-cell immunotherapy of cytomegalovirus disease: a mouse model with 'humanized' antigen presentation as a new preclinical study tool.

Authors:  Niels A W Lemmermann; Matthias J Reddehase
Journal:  Med Microbiol Immunol       Date:  2016-08-18       Impact factor: 3.402

5.  Proteogenomic-based discovery of minor histocompatibility antigens with suitable features for immunotherapy of hematologic cancers.

Authors:  D P Granados; A Rodenbrock; J-P Laverdure; C Côté; O Caron-Lizotte; C Carli; H Pearson; V Janelle; C Durette; E Bonneil; D C Roy; J-S Delisle; S Lemieux; P Thibault; C Perreault
Journal:  Leukemia       Date:  2016-02-09       Impact factor: 11.528

6.  Engineered T cells targeting E7 mediate regression of human papillomavirus cancers in a murine model.

Authors:  Benjamin Y Jin; Tracy E Campbell; Lindsey M Draper; Sanja Stevanović; Bianca Weissbrich; Zhiya Yu; Nicholas P Restifo; Steven A Rosenberg; Cornelia L Trimble; Christian S Hinrichs
Journal:  JCI Insight       Date:  2018-04-19

Review 7.  Re-adapting T cells for cancer therapy: from mouse models to clinical trials.

Authors:  Ingunn M Stromnes; Thomas M Schmitt; Aude G Chapuis; Sunil R Hingorani; Philip D Greenberg
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

Review 8.  Hematopoietic stem cells for cancer immunotherapy.

Authors:  Eric Gschweng; Satiro De Oliveira; Donald B Kohn
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

9.  TCR-ligand dissociation rate is a robust and stable biomarker of CD8+ T cell potency.

Authors:  Mathilde Allard; Barbara Couturaud; Laura Carretero-Iglesia; Minh Ngoc Duong; Julien Schmidt; Gwennaëlle C Monnot; Pedro Romero; Daniel E Speiser; Michael Hebeisen; Nathalie Rufer
Journal:  JCI Insight       Date:  2017-07-20

Review 10.  Planes, Trains, and Automobiles: Perspectives on CAR T Cells and Other Cellular Therapies for Hematologic Malignancies.

Authors:  Saar Gill
Journal:  Curr Hematol Malig Rep       Date:  2016-08       Impact factor: 3.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.